BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20195775)

  • 1. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.
    Slater EP; Langer P; Fendrich V; Habbe N; Chaloupka B; Matthäi E; Sina M; Hahn SA; Bartsch DK
    Fam Cancer; 2010 Sep; 9(3):335-43. PubMed ID: 20195775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
    Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.
    Schneider R; Slater EP; Sina M; Habbe N; Fendrich V; Matthäi E; Langer P; Bartsch DK
    Fam Cancer; 2011 Jun; 10(2):323-30. PubMed ID: 21207249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA2 germline mutations in familial pancreatic carcinoma.
    Hahn SA; Greenhalf B; Ellis I; Sina-Frey M; Rieder H; Korte B; Gerdes B; Kress R; Ziegler A; Raeburn JA; Campra D; Grützmann R; Rehder H; Rothmund M; Schmiegel W; Neoptolemos JP; Bartsch DK
    J Natl Cancer Inst; 2003 Feb; 95(3):214-21. PubMed ID: 12569143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
    Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
    Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of familial pancreatic cancer in Germany.
    Bartsch DK; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Rieder H
    Pancreatology; 2001; 1(5):510-6. PubMed ID: 12120230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
    Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
    J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of BRCA2 mutations in familial pancreatic cancer.
    Couch FJ; Johnson MR; Rabe KG; Brune K; de Andrade M; Goggins M; Rothenmund H; Gallinger S; Klein A; Petersen GM; Hruban RH
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):342-6. PubMed ID: 17301269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
    Chaffee KG; Oberg AL; McWilliams RR; Majithia N; Allen BA; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Petersen GM
    Genet Med; 2018 Jan; 20(1):119-127. PubMed ID: 28726808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
    Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
    J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
    Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
    Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis.
    Limijadi EKS; Muniroh M; Prajoko YW; Tjandra KC; Respati DRP
    PLoS One; 2024; 19(5):e0299276. PubMed ID: 38809921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
    Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
    EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families.
    Rieder H; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Colombo Benkmann M; Eberl T; Grützmann R; Lörken M; Schmidt J; Bartsch DK
    Onkologie; 2002 Jun; 25(3):262-6. PubMed ID: 12119461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
    Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
    Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
    Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
    Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mutations in Japanese familial pancreatic cancer patients.
    Takai E; Yachida S; Shimizu K; Furuse J; Kubo E; Ohmoto A; Suzuki M; Hruban RH; Okusaka T; Morizane C; Furukawa T
    Oncotarget; 2016 Nov; 7(45):74227-74235. PubMed ID: 27732944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.